海角社区

News

Demonstrating Excellence in Outcomes and Culture

LAZCLUZE™ (lazertinib) Now Available from Onco360 for the First-line Treatment, in Combination with Rybrevant庐, of Adult Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have EGFR Exon 19 Deletions or Exon 21 L858R Mutations

Home / News / Specialty Pharmacy / Page 3

Specialty Pharmacy | News

Stay up to date with the latest innovations, company updates, and industry insights as we work to advance health and wellness for all.

Three logos featured: Onco360, Rybrevant, Lazcluze

LAZCLUZE鈩� (lazertinib) Now Available from Onco360

Onco360庐 Has Been Selected as a National Specialty Pharmacy Partner for VORANIGO庐

Onco360 - Rytelo

Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo鈩� (imetelstat)

Onco360 Chief Commercial Officer Named 40 Under 40 in Cancer

OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation

Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya庐 (danicopan)

WHAT PEOPLE ARE SAYING